IP Verse

Rapid-Acting Insulin Compositions - EP3233108

The patent EP3233108 was granted to ELI Lilly on Mar 30, 2022. The application was originally filed on Dec 9, 2015 under application number EP15817678A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3233108

ELI LILLY
Application Number
EP15817678A
Filing Date
Dec 9, 2015
Status
Granted And Under Opposition
Feb 25, 2022
Grant Date
Mar 30, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SCORPIODec 30, 2022SAGITTARIUSADMISSIBLE

Patent Citations (16) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2012178675
DESCRIPTIONUS2013231281
DESCRIPTIONUS2014113856
DESCRIPTIONUS2015065423
EXAMINATIONUS2013231281
EXAMINATIONWO2010102020
INTERNATIONAL-SEARCH-REPORTUS2014357554
INTERNATIONAL-SEARCH-REPORTWO2013158618
OPPOSITIONUS2013231281
OPPOSITIONUS2014357554
OPPOSITIONUS2016082106
OPPOSITIONWO2010102020
OPPOSITIONWO2012174478
OPPOSITIONWO2013158618
OPPOSITIONWO2015120457
OPPOSITIONWO2015173427

Non-Patent Literature (NPL) Citations (8) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Analysis of compositions tested in the patent (following claim amendments) - update to previous D10
OPPOSITION- Anonymous, "Humalog (insulin lispro injection, USP [rDNA original]) for injection", Highlights of Prescribing Information, (20130301), XP093171088
OPPOSITION- Anonymous, "INFORMATION FOR THE PHYSICIAN HUMULIN® R REGULAR INSULIN HUMAN INJECTION, USP, (rDNA ORIGIN) 100 UNITS PER ML (U-100)", (20110301), (20230126), XP093017927
OPPOSITION- Becker, Et Al., "Clinical Pharmacokinetics and Pharmacodynamics of Insulin and Glusline", CLIN. PHARMACOKINET, (20080101), vol. 47, no. 1, XP093017919
OPPOSITION- J Brange, "Stability of Insulin - Studies on the physical and chemical stability of insulin in pharmaceutical formulation", Kluwer Acadamic Publishers Group, (19940101), pages 1 - 59, Kluwer Acadamic Publishers Group, (20190222), XP055560782
OPPOSITION- Rader R, " BIOPHARMACEUTICAL PRODUCTS IN THE U.S. AND EUROPEAN MARKETS", (20070901), XP093017913
OPPOSITION- Winston Crasto, Et Al., "Handbook of Insulin Therapies", (20160101), XP093017935
OPPOSITION- Capelle, M.A.H. Gurny, R. Arvinte, T., "High throughput screening of protein formulation stability: Practical considerations", European journal of pharmaceutics and biopharmaceutics, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM., NL, NL , (20070105), vol. 65, no. 2, doi:10.1016/j.ejpb.2006.09.009, ISSN 0939-6411, pages 131 - 148, XP005823137

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents